Patients with multiple myeloma (MM) have a distinct pattern of second primary malignancy (SPM), with a markedly increased ...
A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis ...
Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
SurvivorNet on MSN
CAR T-cell therapy and the hope for a cure in multiple myeloma
CAR T-cell therapy is a treatment that uses a patient’s own T cells, genetically reprograms them in a lab to recognize ...
A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering ...
Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...
CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina ...
A healthcare provider shares her journey with multiple myeloma, discussing the physical, emotional and financial challenges ...
Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.
A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...
CAR-T and bispecifics in multiple myeloma are reshaping sequencing, enabling earlier use, but access and standardization ...
Pfizer reported that its multiple myeloma therapy Elrexfio met the primary goal in a late-stage study, significantly extending progression-free survival for patients who had received at least one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results